A Canadian multi-centre, open-label long-term study of Pegvisomant treatment in refractory acromegaly

Clinical and Investigative Medicine

Volumn 32, Issue 6, 2009, Pages

  Ezzat, Shereen ^a   Gaspo, Rania ^b   Serri, Omar ^c   Ur, Ehud ^d   Chik, Constance L ^e  

^a UNIVERSITY OF TORONTO   (Canada)

^b PFIZER INC   (United States)

^c NOTRE DAME HOSPITAL   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACROMEGALY; CANADA; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; RECEPTORS, SOMATOTROPIN;

EID: 73249120666     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Thorner MO, Vance ML, Laws Jr, ER, et al: The anterior pituitary. Chapter 9. In: Wilson JD, Foster DW, Kronenberg HM, et al, eds. Williams textbook of endocrinology. 9th Edition. Philadelphia: W.B. Saunders, 1998:259-340.
2. Freda PU: Advances in the diagnosis of acromegaly. Endocrinologist 2000;10:237-44.
3. Rare diseases act. Available from: http://www.pmdfoundation.org/ rarediseasesactof2002. htm [cited July 15, 2009]
4. Duncan E, Wass JA. Investigation Protocol: acromegaly and its investigation. Clin Endocrinol 1999;50:285-93.
5. Swearingen B, Barker FG, Katznelson L, et al. Longterm mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998;83:3419-26.
6. Beauregard C, Truong U, Hardy J, et al. Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol 2003;58:86-91.
7. Biermasz NR, Dekker FW, Pereira AM, et al. Determinants of Survival in Treated Acromegaly in a Single Center: Predictive Value of Serial Insulin-Like Growth Factor I Measurements. J Clin Endocrinol Metab 2004;89:2789-96.
8. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab. 2004;8:667-74.
9. Melmed S. Tight control of growth hormone: an attainable outcome for acromegaly treatment. J Clin Endocrinol Metab 1998;83:3409-10.
10. Patel YC, Ezzat S, Chik CL, et al. Guidelines for the diagnosis and treatment of acromegaly: a Canadian perspective. Clin Invest Med 2000;23:172-87.
11. Klibanski A, Ho K, Freda PU, et al. State-of-the-art strategies for the diagnosis and management of acromegaly. Endocrinologist 2001;11:223-32.
12. Turner HE, Wass JAH. Modern approaches to treating acromegaly. Q J Med 2000;93:1-6.
13. Giustina A, Barkan A, Casanueva, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000;85:526-9.
14. Melmed S, Casanueva FF, Cavagnini F, et al. Guidelines for acromegaly management. J Clin Endocrinol Metab 2002;87:4054-8.
15. Ezzat S, Serri O, Chik CL, et al. Canadian Consensus Guidelines for the diagnosis and management of acromegaly. Clin Invest Med 2006;29:29-39.
16. Swearingen B, Barker FG 2nd, Katznelson L, et al. Long-term mortality after transphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998;83:3419-26.
17. Abosch A, Tyrrell JB, Lamborn KR, et al. Transphenoidal micro-surgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab 1998;83:3411-8.
18. Pfizer Canada Inc. SOMAVERT Product Monograph, September 16, 2008.
19. Parkinson C, Trainer PJ. Growth hormone receptor aantagonists therapy for acromegaly. Baillieres Best Pract Res Clin Endocrinol Metab. 1999;13:419-30.
20. Parkinson C, Trainer PJ. Pegvisomant: a growth hormone receptor antagonist for the treatment of acromegaly. Growth Horm IGF Res 2000;10 Suppl B:S119-23.
21. Kopchick JJ, Parkinson C, Stevens EC, et al. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocrine Rev 2002;23:623-46.
22. Parkinson C, Trainer PJ. The place of pegvisomant in the management of acromegaly. Expert Opin Invest Drugs 2001;10:1725-35.
23. Drake WM, Parkinson C, Besser GM, et al. Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly. Trends Endocrinol Metab. 2001;12:408-13.
24. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000;342:1171-7.
25. Utiger RD. Treatment of acromegaly [Editorial]. N Engl J Med 2000;342:1210-1. [Erratum N Engl J Med 2000;343:76. "On page 1210, on lines 36 and 42-43 of the right-hand column, the term should have been 'dopamine-agonist drugs,' not 'dopamine-antagonist drugs,' as printed."]
26. Van der Lely AJ, Hutson RK, Trainer PJ, et al. Longterm treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001;358:1754-9.
27. Neggers SJ, de Herder WW, Janssen JA, et al. Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur J Endocrinol. 2009;160:529-33.
28. Ezzat S, Forster MJ, Berchtold P, et al. Acromegaly: clinical and biochemical features in 500 patients. Medicine (Baltimore) 1994;73:233-40.
29. Ezzat S, Snyder PJ, Young WF, et al. Octreotide treatment of acromegaly: a randomized, multicenter study. Ann Intern Med. 1992;117:711-8.
30. Freda PU, Katznelson L, van der Lely AJ, et al. Longacting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2005;90:4465-73.
31. Feenstra J, de Herder WW, ten Have SM, et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet. 2005;365:1644-6.
32. Trainer PJ, Ezzat S, D'Souza GA, et al. A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clin Endocrinol (Oxf). 2009;71:549-57.